Enhancing Tumor Necrosis Factor Activity with Monoclonal Antibody
Author Information
Author(s): D.A. Rathjen, L.J. Furphy, R. Aston
Primary Institution: Peptide Technology Ltd.
Hypothesis
Can a monoclonal antibody enhance the tumor necrotic activity of TNF without inhibiting its binding to tumor cells?
Conclusion
The study found that a specific monoclonal antibody can significantly enhance the tumor regressive activity of TNF while inhibiting its toxic effects on endothelial cells.
Supporting Evidence
- Monoclonal antibody MAb 32 did not inhibit TNF binding to tumor cells but inhibited its effects on endothelial cells.
- Treatment with TNF-MAb 32 complex resulted in a 5- to 10-fold enhancement in tumor regression.
- FAb' fragments of MAb 32 showed similar enhancement of TNF activity as the intact antibody.
Takeaway
Researchers discovered that a special antibody can help a substance that fights tumors work better without making people sick.
Methodology
The study involved treating tumor-bearing mice with TNF and a monoclonal antibody, measuring tumor size and activity.
Limitations
The study was limited to specific tumor models and may not generalize to all types of tumors.
Participant Demographics
Female BALB/c mice aged 10-12 weeks were used in the experiments.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Want to read the original?
Access the complete publication on the publisher's website